Insulin lispro

Subcutaneous
Diabetes mellitus

Decreased dose may be necessary.

Decreased dose may be necessary.

Should be taken with food. Administer w/in 15 min before or immediately after meals.

Hypoglycaemia.

Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections.

Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj (rotate Inj site).

IV/SC: B

Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by β-blockers, clonidine.

Description: Insulin lispro, a rapid-acting analog of human insulin, lowers blood glucose levels. It regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal.
Onset: 15-30 min
Duration: 3-6.5 hrs.

Insulin Preparations